ClinicalTrials.gg
CompletedNCT04231448DEBUpdated Apr 8, 2026

Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL

A Phase 3 interventional study of R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) and Tucidinostat in Diffuse Large B-cell Lymphoma, sponsored by Chipscreen Biosciences, Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Chipscreen Biosciences, Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
423
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing tucidinostat in Lymphoma, Large B-Cell, Diffuse — 11 open to participants now, 11 under way, 2 of them phase 3. tucidinostat · Lymphoma, Large B-Cell, Diffuse.

Enrollment
2nd of 20
423 · median 61
Started
2020
the only one that year
Phase 3
3 of 20
2 open now
Registered
8th of 20
by date
Lead sponsor
1 of 20
Chipscreen Biosciences, Ltd.

Among the 20 studies testing tucidinostat in Lymphoma, Large B-Cell, Diffuse, this one is the 2nd largest by enrollment, is the only one that started in 2020, is one of 3 in phase 3, and was the 8th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

11 of the 20 studies testing tucidinostat in Lymphoma, Large B-Cell, Diffuse are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

About tucidinostat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing tucidinostat in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

Tucidinostat (formerly known as chidamide) is an oral subtype-selective histone deacetylase inhibitor. This Randomized, Double-blind, Placebo-controlled Phase 3 trail is studying the efficacy and safety of Tucidinostat, in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed MYC/BCL2 Double-Expressor Diffuse Large B-cell Lymphoma.

Read the detailed description

The primary objective is to evaluate if the addition of Tucidinostat to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) prolongs event-free survival (EFS) compared with R-CHOP alone in subjects with newly diagnosed MYC/BCL2 Double-Expressor subtype of DLBCL selected by IHC and FISH.

03

Conditions studied

  • Diffuse Large B-cell Lymphoma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Each potential subject must satisfy all of the following criteria to be enrolled in the study.

    1. Male or female, age ≥ 18 years and ≤80 years.
    2. No prior treatment for diffuse large B cell lymphoma(DLBCL), including hemotherapy, immunotherapy; radiotherapy (excluding local radiotherapy); monoclonal antibody therapy; surgical treatment (excluding )
    3. Histological or cytological confirmation of DLBCL

    <!-- -->

    1. CD20-positive DLBCL;
    2. Myc≥40% as well as Bcl-2≥50% through immunohistochemistry;
    3. Not with double (BCL-2 and c-MYC gene rearrangement) or triple (BCL-2, BCL-6, and c-MYC gene rearrangement) hit by FISH.

The verification of DLBCL will be based on local pathology report.15-20 unstained slides must be sent to the central laboratory for retrospective confirmation.

4.At least one positive lesion according to the Lugano Classification by fluorodeoxyglucose (FDG) positron emission tomography (PET)-computed tomography(CT).

5.Lymphoma International PrognosisIndex (IPI) score of 2,3,4. 6. performance status grade of 0, 1, or 2. 7.Laboratory criteria are as follows except that caused by lymphoma assessed by the investigator (without receiving any supportive treatment for the following parameters within 2 weeks from the last dose prior to study entry):

(1)Hematology values: (Hb)≥90g/L ; (ANC) ≥1.5×109/L ; ≥90×109/L (2)Biochemical values: Serum creatinine ≤1.5×(ULN); Total ≤1.5 × ULN; (ALT), Aspartate aminotransferase (AST) ≤2.5×ULN(ALT,AST≦5×ULN if liver involved).

8.Expected survival≥6 months. 9.All patients must have signed an document.

Exclusion criteria

Exclusion Criteria:

  • Any potential subject who meets any of the following criteria will be excluded from participating in the study.

    1. Presence of CNS involvement.
    2. Patients with primary DLBCL of the central nervous system (CNS),or secondary lymphoma of the central nervous system, or Primary mediastinal (thymic) large B-cell lymphoma, or Primary effusion lymphoma, or B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma, or Primary cutaneous DLBCL, leg type, or indolent lymphoma, or Burkitt lymphoma, or EBV-positive mucocutaneous ulcer, or DLBCL associated with chronic inflammation, or Lymphomatoid granulomatosis, or Intravascular large B-cell lymphoma, or ALK-positive large B-cell lymphoma, or Plasmablastic lymphoma, or HHV8-positive DLBCL, NOS, or primary testicular DLBCL.
    3. Patients with transformed lymphoma.
    4. History of organ transplantation or hematopoietic stem cell transplantation.
    5. Patients planned for or allogeneic transplant as consolidation in .
    6. Patients with any other , except patients with a history of curatively treated basal or squamous cell carcinoma or in situ carcinoma of the cervix at any time prior to the study are eligible.
    7. Prior treatment with cytotoxic drugs for another condition (e.g., rheumatoid arthritis) or prior use of an anti-CD20 antibody within 5 years of the start of Cycle 1.
    8. Prior use of any monoclonal antibody within 3 months of the start of Cycle 1.
    9. Any therapy within 3 months prior to the start of Cycle 1.
    10. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products.
    11. to any of the individual components of CHOP.
    12. use > 30 mg/day of prednisone or equivalent, for purposes other than lymphoma symptom control:

    <!-- -->

    1. Patients receiving corticosteroid treatment with ≤ 30 mg/day of prednisone or equivalent must be documented to be on a stable dose of at least 4 weeks' duration prior to randomization (Cycle 1, Day 1).
    2. If glucocorticoid treatment is urgently required for lymphoma symptom control prior to the start of study treatment, prednisone 100 mg or equivalent could be given for a maximum of 5 days, but all tumor assessments must be completed prior to start of glucocorticoid treatment.

    13.Ongoing serious central nervous system disease or peripheral neuropathy, such as progressive multifocal leukoencephalopathy.

    14.Have uncontrolled or significant cardiovascular disease, including:

    1. Grade II or higher Congestive heart failure, unstable angina pectoris, myocardial infarction ( Functional Classification ) within 6 months prior to study entry; or arrhythmia requiring treatment, or (LVEF) \< 50% during screening stage.
    2. Primary cardiomyopathy (dilated cardiomyopathy, hypertrophic cardiomyocyte, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, et,al).
    3. History of significant prolongation, or Corrected QT Interval QTc≥450ms(male), QTc≥470ms(female)at screening.
    4. Symptomatic coronary heart disease requiring treatment.
    5. Any other cardiovascular disease which is inappropriate for the study according to investigators' judgment.

    15.History of interstitial lung disease(ILD), or with ongoing signs and symptoms by CT or MRI at the time of screening.

    16.Patients with factors that could affect oral medication (such as dysphagia, chronic diarrhea, intestinal obstruction etc), or undergone gastrectomy.

    17.History of deep vein thrombosis or pulmonary embolism. 18.History of active bleeding within 2 months prior to the start of Cycle 1;or patients receiving anticoagulation therapy; or patients with evidence of bleeding potential according to investigators' judgment ( esophageal varices, active ulcer, or fecal occult blood test positive etc. ). Patients with bleeding led by lymphoma according to investigators' judgment are eligible.

19.6 weeks or less from the last major surgery that involved crucial organs, or with any other factors impede postoperative recovery according to investigators' judgment.

20.Known active infection, or active and uncontrolled infection(HBV), Virus(HCV), (HIV)/AIDS (Acquired Immune Deficiency Syndrome), or any other serious infection. (active infection defined as any major episode of infection requiring systemic treatment; Patients with occult or prior HBV may be included if HBV DNA is undetectable.) 21.Any mental or cognitive disorder, that would impair the ability to understand the document, or limit compliance with study requirements/ treatment.

22.Drug or alcohol abuse. 23.Women of and men who are sexually active not willing to practice a highly effective method of during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials.These restrictions apply for 12 months after the last dose of rituximab or 12 weeks after the last dose of study drug, whichever is later. Pregnancy or lactation.

24.Any other condition which is inappropriate for the study according to investigators' judgment.

Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
423 participants (actual)

Study arms

  • Experimental
    CR-CHOP

    Drug: R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) · Drug: Tucidinostat

  • Placebo comparator
    R-CHOP

    Drug: R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) · Drug: Placebo

Interventions

  • DrugR-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone)

    R-CHOP : rituximab 375 mg/m2 IV, cyclophosphamide 750 mg/m2 IV, doxorubicin 50 mg/m2 IV, vincristine 1.4 mg/m2 IV \[maximum total 2 mg\], and prednisone \[or equivalent\] 100 mg orally as the background therapy for 6 cycles (21 days/cycle).

  • Tucidinostat :30 mg was given orally after breakfast on day 1, day 4, day 8, day 11 in a 21-day cycle,for 6 cycles. After cycle 6 patients who are evaluated as complete response will receive 24 weeks additional administrations of Tucidinostat on day 1, day 4, day 8, day 11 in a 21-day cycle.

  • DrugPlacebo

    Placebo:30 mg was given orally after breakfast on day 1, day 4, day 8, day 11 in a 21-day cycle,for 6 cycles. After cycle 6 patients who are evaluated as complete response will receive 24 weeks additional administrations of placebo on day 1, day 4, day 8, day 11 in a 21-day cycle.

06

What researchers measure

Primary outcomes

  1. Event Free Survival (EFS)

    Defined as the duration from the date of randomization to the date of disease progression, relapse from CR , initiation of subsequent systemic antilymphoma therapy for residual disease, or death, whichever occurs first.

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. Complete Response Rate(CRR)

    Defined as the proportion of subjects with measurable disease who achieve CR.

    Time frame: Up to approximately 3 years

  2. Progression-Free Survival (PFS)

    Defined as the duration from the date of randomization to the date of progression, relapse from CR, or death, whichever occurred first.

    Time frame: Up to approximately 5 years

  3. Overall Survival (OS)

    defined as the duration from the date of randomization to the date of the participant's death

    Time frame: Up to approximately 5 years

  4. Disease-Free Survival (DFS)

    Defined for patients achieving CR as the period from the date of the initial CR until the date of relapse or death from any cause.

    Time frame: Up to approximately 5 years

  5. Safety of Tucidinostat when combined with R-CHOP

    All adverse events occurring during or after the first treatment will be summarized by treatment arm and NCI CTCAE grade.

    Time frame: Up to approximately 5 years

07

Study locations

2 sites
  • Peking University Cancer Hospital
    Beijing, Beijing Municipality, China
  • Shanghai JiaoTong University School of Medicine,Ruijin Hospital
    Shanghai, Shanghai Municipality, China
08

References and documents

Publications

  • Xu PP, Song YQ, Shen JZ, Cai QQ, Zhou H, Zhang LL, Xiang Y, Sun XH, Yang W, Yao ZH, Jing HM, Wen SJ, Jin J, Xue HW, Cen H, Ding KY, Jin ZM, Liu LH, Xing XJ, Li LF, Hou M, Liu L, Zhang MZ, Li WY, Bai O, Feng R, Zhu ZM, Wu HJ, Su LP, Gao L, Li F, Huang WR, Liu P, Yan XJ, Zhao Y, Su H, Zhao XL, Fu R, Liu H, Shi WY, Li HZ, Chen B, Ning ZQ, Zhu J, Zhao WL. Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial. JAMA. 2026 May 19;335(19):1684-1693. doi: 10.1001/jama.2026.4199. PubMed 42018318 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Jan 2023, 31 months.

Of 37 industry-sponsored phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's 31 months is below that.

Counting every sponsor, half of 73 studies reached it within 57 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2020
First posted
Jan 18, 2020
StartActual
May 21, 2020
Primary completionActual
Jan 10, 2023
CompletionActual
Jun 29, 2025
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04231448
Responsible party
Sponsor
First posted
Jan 18, 2020
Start date
May 21, 2020
Primary completion
Jan 10, 2023
Completion
Jun 29, 2025
Last update
Apr 8, 2026

Study contacts

Weili Zhao, Professor
principal investigator · Shanghai JiaoTong University School of Medicine,Ruijin Hospital
Jun Zhu, Professor
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tucidinostat

Start the discussion